|
ACIP votes for changes to Bexsero (MenB), pneumococcal, and COVID-19 vaccine recommendations
Heidi Gurov, RN, Nurse Consultant
The Advisory Committee on Immunization Practices (ACIP) voted for new changes to the recommendations for Bexsero (GSK MenB vaccine), pneumococcal, and COVID-19 vaccines. The Centers for Disease Control and Prevention (CDC) director has adopted these recommendations. They are official and are to be used immediately.
Pneumococcal vaccines
ACIP recommends a pneumococcal conjugate vaccine (PCV) for all PCV-naïve adults aged ≥50 years.
COVID-19 vaccines
In addition to the previously recommended 2024-2025 vaccination:
- ACIP recommends a second dose* of 2024-2025 COVID-19 vaccine for adults ages 65 years and older
- ACIP recommends a second dose** of 2024-2025 COVID-19 vaccine for people ages 6 months-64 years who are moderately or severely immunocompromised
-
ACIP recommends additional doses (i.e., 3 or more doses) of the 2024-2025 COVID-19 vaccine for people ages 6 months and older who are moderately or severely immunocompromised under shared clinical decision-making
*If previously unvaccinated and receiving Novavax, 2 doses are recommended as initial vaccination series followed by a third dose of any age-appropriate 2024-2025 COVID-19 vaccine 6 months (minimum interval 2 months) after the second dose.
**If previously unvaccinated or receiving initial vaccination series, at least 2 doses of 2024-2025 vaccine is recommended, and depending on vaccination history, more may be needed. This additional 2024-2025 vaccine dose is recommended 6 months (minimum interval 2 months) after completion of the initial vaccination series.
Meningococcal vaccines
ACIP recommends MenB-4C (Bexsero) be administered as a 2-dose series at 0 and 6 months when given to healthy adolescents and young adults aged 16-23 years based on shared clinical decision-making for the prevention of serogroup B meningococcal disease.
ACIP recommends MenB-4C (Bexsero) be administered as a 3-dose series at 0, 1-2, and 6 months when given to persons aged ≥10 years at increased risk for serogroup B meningococcal disease (i.e., persons with anatomic or functional asplenia, complement component deficiencies, or complement inhibitor use; microbiologists routinely exposed to N. meningitidis isolates; and persons at increased risk during an outbreak).
Healthy adolescents who have completed a previous series of Bexsero under the 0 and 1 month schedule do not need to be recalled for further vaccination.
Immunization schedules
Additionally, ACIP approved the 2025 immunization schedules, which will be published at a future date. Information will be emailed when they are available at https://www.cdc.gov/acip/vaccine-recommendations/index.html.
The Wyoming Immunization Registry (WyIR) forecast will not reflect these changes at this time. Please consult other resources and methods to ensure appropriate vaccination is recommended, and minimum intervals are being met.
Please reach out to Nurse Consultant Heidi Gurov with any questions! heidi.gurov@wyo.gov or 307-777-8981.
|